Stockreport

AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn's Disease [Yahoo! Finance]

AbbVie Inc.  (ABBV) 
Last abbvie inc. earnings: 5/1 07:43 am Check Earnings Report
US:NYSE Investor Relations: investors.abbvie.com/investor-overview
PDF disease, risankizumab (SKYRIZI ® ) achieved superiority for the co-primary and ranked secondary endpoints at week 12 for induction delivered by subcutaneous (SC) injecti [Read more]